Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialKausik K Ray, Helen M Colhoun, Michael Szarek et al.|The Lancet Diabetes & Endocrinology|2019Cited by 330